ArticleTurkish journal of haematology : official journal of Turkish Society of Haematology2025
Identification of TRAPPC4 as a Key Autoantigen in Immune-Related Pancytopenia: Epitope Characterization and Immune Activation Mechanisms
Article in Turkish journal of haematology : official journal of Turkish Society of Haematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Immune-related pancytopenia (IRP) is characterized by autoantibody-mediated destruction or suppression of bone marrow cells, leading to pancytopenia. This study aimed to explore the role of trafficking protein particle complex subunit 4 (TRAPPC4) as a key autoantigen in IRP, including epitope identification and immune activation mechanisms. Materials and Methods: A total of 90 participants were included in the study, divided into four groups: 30 newly diagnosed IRP patients, 25 patients with IRP in remission, 20 patients with other hematological conditions (severe aplastic anemia [SAA] and myelodysplastic syndrome [MDS]) as a patient control group, and 15 healthy individuals as a healthy control group. TRAPPC4 was identified using affinity screening with a phage-display random peptide library and confirmed with ELISPOT and epitope prediction software. TRAPPC4 expression in bone marrow cells and serum antibody titers was assessed via flow cytometry, ELISA assay, and real-time polymerase chain reaction. Immune cell profiling of peripheral blood mononuclear cells was conducted using flow cytometry. Results: TRAPPC4 was overexpressed in the CD34+ bone marrow hematopoietic progenitor cells of newly diagnosed IRP patients compared to patients in remission, the patient control group (SAA and MDS), and the healthy control group, with no significant differences observed for CD15+ granulocytes or CD235a+ nucleated red blood cells. The epitope peptide YTADGKEVLEYLG activated Th2 cells, as confirmed by ELISPOT. Newly diagnosed IRP patients exhibited elevated TRAPPC4 mRNA and protein levels in bone marrow mononuclear cells and higher serum antibody titers compared to controls. Immune profiling revealed increased CD19+ and CD5+CD19+ B lymphocytes in IRP patients. Conclusion: TRAPPC4 was found to be a key autoantigen in IRP along with CD34+ cells as primary targets of autoantibody attacks. The identification of TRAPPC4 and its epitope provides insights into IRP pathogenesis and suggests potential diagnostic and therapeutic strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.